Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Arvinas, Inc. (NASDAQ:ARVN) has earned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $61.08.

A number of equities analysts recently issued reports on the company. Oppenheimer decreased their price objective on Arvinas from $50.00 to $40.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. BMO Capital Markets lowered their price target on Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a report on Wednesday, November 20th. HC Wainwright reaffirmed a “buy” rating and issued a $87.00 price objective on shares of Arvinas in a report on Thursday, October 31st. Finally, Stephens assumed coverage on shares of Arvinas in a research note on Monday, November 18th. They set an “overweight” rating and a $55.00 target price on the stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ARVN. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after acquiring an additional 440 shares during the last quarter. Amalgamated Bank increased its stake in Arvinas by 29.6% in the 2nd quarter. Amalgamated Bank now owns 2,223 shares of the company’s stock worth $59,000 after purchasing an additional 508 shares in the last quarter. Edgestream Partners L.P. raised its holdings in Arvinas by 16.3% during the 2nd quarter. Edgestream Partners L.P. now owns 9,311 shares of the company’s stock worth $248,000 after buying an additional 1,305 shares during the period. Quest Partners LLC acquired a new stake in Arvinas during the 2nd quarter worth about $42,000. Finally, nVerses Capital LLC purchased a new stake in Arvinas during the third quarter valued at about $39,000. Institutional investors own 95.19% of the company’s stock.

Arvinas Stock Performance

Shares of ARVN opened at $26.72 on Monday. The firm has a fifty day moving average of $25.68 and a 200-day moving average of $26.74. The company has a market cap of $1.84 billion, a price-to-earnings ratio of -5.72 and a beta of 1.96. Arvinas has a 1 year low of $21.17 and a 1 year high of $53.08.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.20. The firm had revenue of $102.40 million for the quarter, compared to analyst estimates of $60.56 million. During the same period in the previous year, the firm earned ($1.18) earnings per share. The company’s revenue for the quarter was up 196.0% on a year-over-year basis. Analysts predict that Arvinas will post -3.24 EPS for the current year.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.